NASDAQ:ACTU Actuate Therapeutics (ACTU) Stock Price, News & Analysis $8.29 +0.28 (+3.50%) (As of 02:52 PM ET) Add Compare Share Share Today's Range$7.88▼$8.3050-Day Range N/A52-Week Range$7.33▼$10.16Volume22,661 shsAverage Volume40,429 shsMarket Capitalization$158.42 millionP/E Ratio55.27Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends Get Actuate Therapeutics alerts: Email Address Ad DTII’ve got to share this with youToday, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman About Actuate Therapeutics Stock (NASDAQ:ACTU)Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Read More ACTU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACTU Stock News HeadlinesAugust 17, 2024 | insidertrades.comActuate Therapeutics (NASDAQ:ACTU) Insider Todd S. Thomson Sells 18,750 SharesSeptember 11, 2024 | finanznachrichten.deActuate Therapeutics: Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue SarcomasSeptember 16, 2024 | DTI (Ad)I want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.September 11, 2024 | marketwatch.comActuate Gets FDA Orphan Designation for Elraglusib in Soft Tissue SarcomasSeptember 11, 2024 | americanbankingnews.comContrasting Actuate Therapeutics (ACTU) and Its CompetitorsSeptember 9, 2024 | globenewswire.comActuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing SarcomaSeptember 5, 2024 | globenewswire.comActuate to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 18, 2024 | investing.comActuate therapeutics insider sells $150,000 worth of sharesSeptember 16, 2024 | DTI (Ad)I want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.August 17, 2024 | investing.comActuate Therapeutics Inc (ACTU)August 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust FinancialsAugust 15, 2024 | ca.finance.yahoo.comActuate Therapeutics, Inc. Common stock (ACTU)August 14, 2024 | globenewswire.comActuate Therapeutics Announces Closing of Initial Public OfferingAugust 12, 2024 | globenewswire.comActuate Therapeutics Announces Pricing of Initial Public OfferingSee More Headlines Receive ACTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACTU Previous SymbolNASDAQ:ACTU CUSIPN/A CIK1652935 WebN/A Phone(847) 986-4190FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio55.27 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares19,110,000Free FloatN/AMarket Cap$158.42 million OptionableN/A BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Daniel M. Schmitt (Age 62)CEO, President & Director Comp: $520kDr. Andrew P. Mazar Ph.D. (Age 62)Co-Founder & COO Comp: $607.5kDr. Alan Kozikowski Ph.D. (Age 73)Scientific Founder and Advisor Mr. Paul J. Lytle CPA (Age 56)Chief Financial Officer Key CompetitorsREGENXBIONASDAQ:RGNXY-mAbs TherapeuticsNASDAQ:YMABAstria TherapeuticsNASDAQ:ATXSVectivBioNASDAQ:VECTSIGA TechnologiesNASDAQ:SIGAView All CompetitorsInsidersEquity Cof Lp BiosBought 500,000 shares on 8/14/2024Total: $4 M ($8.00/share)Todd S ThomsonSold 18,750 sharesTotal: $150,000.00 ($8.00/share)Leslie W KreisSold 24,999 sharesTotal: $224,991.00 ($9.00/share)View All Insider Transactions ACTU Stock Analysis - Frequently Asked Questions How have ACTU shares performed this year? Actuate Therapeutics' stock was trading at $8.61 on January 1st, 2024. Since then, ACTU shares have decreased by 3.7% and is now trading at $8.29. View the best growth stocks for 2024 here. When did Actuate Therapeutics IPO? Actuate Therapeutics (ACTU) raised $27 million in an IPO on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners served as the underwriter for the IPO and Newbridge Securities Corp. was co-manager. When does Actuate Therapeutics' quiet period expire? Actuate Therapeutics' quiet period expires on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its initial public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During Actuate Therapeutics' quiet period, insiders and underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Actuate Therapeutics? Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACTU) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
